Tamara Tugal
Keine laufenden Positionen mehr
Profil
Tamara Tugal worked as a Director of Business Development at Amsterdam Molecular Therapeutics (AMT) Holding NV, a Manager of Business Development at Allergan Biologics Ltd., and a Vice President of Business Development at Lanthio Pharma BV.
She received an undergraduate degree from The University of Edinburgh, a doctorate from University College London, and an MBA from London Business School.
Ehemalige bekannte Positionen von Tamara Tugal
| Unternehmen | Position | Ende |
|---|---|---|
Allergan Biologics Ltd.
 Allergan Biologics Ltd. BiotechnologyHealth Technology Part of Pharmaron Beijing Co., Ltd., Allergan Biologics Ltd. develops biologics products. The company is based in Liverpool, UK. The British company was founded in 2002 by Bernard Chan. Allergan Biologics was acquired by Pharmaron Biologics (UK) Holdings Ltd. from AbbVie, Inc. on April 30, 2021 for $165.95 million. | Corporate Officer/Principal | - |
Lanthio Pharma BV
 Lanthio Pharma BV Medical SpecialtiesHealth Technology Lanthio Pharma BV focuses on discovering and developing lantipeptides for the generation of novel peptide therapeutics. Its product is a lanthionine-stabilized specific agonist of the AT2 receptor, which has great potential in diseases where tissue protection is important, like fibrosis. The company was founded in 2010 and is headquartered in Groningen, the Netherlands. | Corporate Officer/Principal | - |
Amsterdam Molecular Therapeutics (AMT) Holding NV
 Amsterdam Molecular Therapeutics (AMT) Holding NV Miscellaneous Commercial ServicesCommercial Services Amsterdam Molecular Therapeutics (AMT) Holding NV engages in the development of human gene based therapies. The company has a product pipeline of several gene therapy products in development for hemophilia B, acute intermittent porphyria, Parkinson's disease and SanfilippoB. It is expected to be finally dissolved in September 2012. Amsterdam Molecular Therapeutics (AMT) Holding was founded by Sander J. H. van Deventer and John J. P. Kastelein on March 20, 1998 and is headquartered in Amsterdam, Netherlands. | Corporate Officer/Principal | - |
Ausbildung von Tamara Tugal
| London Business School | Masters Business Admin |
| The University of Edinburgh | Undergraduate Degree |
| University College London | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 3 |
|---|---|
Amsterdam Molecular Therapeutics (AMT) Holding NV
Amsterdam Molecular Therapeutics (AMT) Holding NV Miscellaneous Commercial ServicesCommercial Services Amsterdam Molecular Therapeutics (AMT) Holding NV engages in the development of human gene based therapies. The company has a product pipeline of several gene therapy products in development for hemophilia B, acute intermittent porphyria, Parkinson's disease and SanfilippoB. It is expected to be finally dissolved in September 2012. Amsterdam Molecular Therapeutics (AMT) Holding was founded by Sander J. H. van Deventer and John J. P. Kastelein on March 20, 1998 and is headquartered in Amsterdam, Netherlands. | Commercial Services |
Allergan Biologics Ltd.
Allergan Biologics Ltd. BiotechnologyHealth Technology Part of Pharmaron Beijing Co., Ltd., Allergan Biologics Ltd. develops biologics products. The company is based in Liverpool, UK. The British company was founded in 2002 by Bernard Chan. Allergan Biologics was acquired by Pharmaron Biologics (UK) Holdings Ltd. from AbbVie, Inc. on April 30, 2021 for $165.95 million. | Health Technology |
Lanthio Pharma BV
Lanthio Pharma BV Medical SpecialtiesHealth Technology Lanthio Pharma BV focuses on discovering and developing lantipeptides for the generation of novel peptide therapeutics. Its product is a lanthionine-stabilized specific agonist of the AT2 receptor, which has great potential in diseases where tissue protection is important, like fibrosis. The company was founded in 2010 and is headquartered in Groningen, the Netherlands. | Health Technology |